Brian M Frier

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 11

Top Venues

Diabetes, obesity & metabolism

Diabetes therapy : research, treatment and education of diabetes and related disorders

University of Edinburgh

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Edinburgh

United Kingdom

Honorary Professor of Diabetes

Publications

Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (8) (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (8) (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (8) (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial. Diabetes, obesity & metabolism (2023)
Vivian T Thieu, Beth D Mitchell, Oralee J Varnado, Brian M Frier
Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon. Diabetes, obesity & metabolism 22 (4) (2020)
David R Owens, Wolfgang Landgraf, Brian M Frier, Mei Zhang, Philip D Home, Stephen H Mandy, Geremia B Bolli
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0. Diabetes, obesity & metabolism 21 (2) (2019)
Brian M Frier, Alexandria Ratzki-Leewing, Stewart B Harris
Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus. Diabetes, obesity & metabolism 21 (7) (2019)
Alison J Dunkley, Claire Fitzpatrick, Laura J Gray, Ghazala Waheed, Simon R Heller, Brian M Frier, Melanie Jane Davies, Kamlesh Khunti F MedSci, null null
Incidence and severity of hypoglycaemia in type 2 diabetes by treatment regimen: A UK multisite 12-month prospective observational study. Diabetes, obesity & metabolism 21 (7) (2019)
Wolfgang Landgraf, David R Owens, Brian M Frier, Mei Zhang, Geremia B Bolli
Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL. Diabetes, obesity & metabolism 22 (3) (2019)
Brian M Frier, Wolfgang Landgraf, Mei Zhang, Geremia B Bolli, David R Owens
Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus. Diabetes, obesity & metabolism 20 (12) (2018)

Brian M Frier.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Brian M Frier